NCT04759534 - Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 10, 2020

Primary Completion Date

October 30, 2021

Study Completion Date

November 30, 2021

Conditions

Efficacy and SafetyHeterozygous Familial HypercholesterolemiaPCSK9

Interventions

BIOLOGICAL

protein convertase subtilisin/kexin type 9 inhibitor

IBI306 is a kind of protein convertase subtilisin/kexin type 9 inhibitor.Received abdominal subcutaneous injection of IBI306 150 mg Q2W or 300 mg Q4W

Trial Locations (1)

xili People's Hospital, Shenzhen